Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation

CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLernâ„¢ AI-Driven Discovery LEHI, Utah, March 14, 2025 /PRNewswire/ — Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the cryo-electron…